Search

This document provides a list of drugs associated with non-serious adverse events identified in the scientific literature over the last week. The table includes the drug names, the adverse events reported, and the number of cases. Some of the adverse events mentioned include joint disorders, abdominal pain, alopecia, dizziness, fatigue, nausea, and skin disorders. It is important to note that this information is based on case reports and should be interpreted with caution. [Extracted from the article]

This document provides a list of drugs associated with non-serious adverse events identified in the scientific literature over the last week. The table includes the drug names, the adverse events reported, and the number of cases. Some of the adverse events mentioned include joint disorders, abdominal pain, alopecia, dizziness, fatigue, nausea, and skin disorders. It is important to note that this information is based on case reports and should be interpreted with caution. [Extracted from the article]

A retrospective study of 24 patients with nasopharyngeal carcinoma found that some patients developed hyperthyroidism or experienced a lack of efficacy during treatment with bleomycin, epirubicin, cisplatin, ifosfamide, etoposide, and carboplatin. One patient developed hyperthyroidism as a result of the treatment, while another patient did not respond to the treatment and ultimately died from progressive nasopharyngeal carcinoma. The study does not provide information about the ages or genders of the patients, nor does it specify the routes, dosages, or duration of treatment that led to these reactions. [Extracted from the article]

A 47-year-old woman with large B-cell lymphoma developed cytomegalovirus colitis while receiving axicabtagene-ciloleucel treatment. She also experienced lack of efficacy during treatment with cyclophosphamide, doxorubicin, etoposide, prednisone, rituximab, and vincristine. After being refractory to the initial treatment, she received chimeric antigen receptor-T cell (CAR-T) therapy and developed haematochezia with haemodynamic instability. Colonoscopy revealed ulcers and active bleeding, and CMV immunostaining and viral load confirmed cytomegalovirus colitis. Treatment with ganciclovir improved her condition. [Extracted from the article]

In a retrospective study of 122 adults treated for primary mediastinal large B-cell lymphoma (PMBL), a patient exhibited lack of effectiveness during treatment with a combination of etoposide phosphate, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab. The patient initially received a cycle of the R-CHOP regimen, followed by five courses of the R-DA-EPOCH regimen. However, the disease progressed, indicating a lack of efficacy. The study highlights the need for further research and alternative treatment options for PMBL. [Extracted from the article]

In a case series involving two patients, a 14-year-old boy and a 9-year-old boy, both exhibited lack of efficacy during their respective cancer treatments. The first patient, who had a history of kidney transplant, initially received rituximab monotherapy for a large B-cell neoplasm but experienced disease progression. He then underwent chemoimmunotherapy with bortezomib, cyclophosphamide, dexamethasone, and daratumumab, but relapsed while on therapy. After further examination, he was diagnosed with posttransplant plasmablastic lymphoma and received EPOCH chemotherapy, achieving remission. The second patient, who had a history of heart transplant, underwent surgery for intestinal obstruction and was subsequently diagnosed with posttransplant plasmablastic lymphoma. He received EPOCH chemotherapy with bortezomib but unfortunately died due to lack of efficacy. [Extracted from the article]

A retrospective study was conducted on 78 patients with metastatic non-small cell lung cancer, and one patient was described who experienced a lack of efficacy during treatment with pembrolizumab. The patient's disease progressed despite receiving pembrolizumab, and they subsequently received second-line treatment with cisplatin and etoposide. The specific details regarding the patient's age, sex, and treatment outcomes were not provided in the article. [Extracted from the article]

A case report published in Reactions Weekly describes the lack of efficacy of carboplatin and etoposide in the treatment of primary hepatic neuroendocrine carcinoma in a 65-year-old man. The patient, who also had type 2 diabetes, initially presented with abdominal pain and was treated with piperacillin/tazobactam. After further examination, the diagnosis of primary hepatic neuroendocrine carcinoma was confirmed, and the patient began receiving carboplatin. He was later discharged from the hospital and prescribed etoposide. However, despite receiving both medications, the patient's condition worsened, and he ultimately died. [Extracted from the article]

In a retrospective study of 11 patients with diffuse large B-cell lymphoma (DLBCL), 10 patients experienced various toxicities during treatment with multiple drugs, including cyclophosphamide, doxorubicin, etoposide, prednisone, rituximab, venetoclax, and vincristine. The toxicities reported included neutropenia, febrile neutropenia, thrombocytopenia, anemia, sepsis, pulmonary infection, diarrhea, nausea, vomiting, and decreased fibrinogen. The study did not provide information on the patients' ages, sexes, duration of treatments, or outcomes. [Extracted from the article]

A 20-year-old man with no relevant medical history was diagnosed with primary brain alveolar rhabdomyosarcoma (ARMS) and underwent surgery. He then started chemotherapy with vincristine, dactinomycin, and cyclophosphamide, but serial MRI scans showed no shrinkage of the tumors. Radiotherapy and additional chemotherapy regimens were added, but there was still no therapeutic response, and the lesions continued to grow. The man eventually died from primary brain ARMS six months after surgery. The lack of efficacy was observed with the drugs vincristine, dactinomycin, cyclophosphamide, doxorubicin, ifosfamide, and etoposide. [Extracted from the article]

A case report published in Reactions Weekly describes a patient with Hodgkin's lymphoma who developed oesophageal perforation during treatment with etoposide and melphalan. The patient underwent autologous stem cell transplantation with a high dose of filgrastim, and subsequently experienced oesophageal perforation as a result of the etoposide and melphalan therapy. Unfortunately, the patient died due to this complication. This study, conducted between 1992 and 2022, highlights a serious adverse event associated with this treatment regimen. [Extracted from the article]

In a randomized prospective pilot study, a patient with non-small cell lung cancer developed bone marrow depression during treatment with cisplatin and etoposide. The patient underwent pulmonary resection and received chemotherapy followed by radiation therapy. However, the patient experienced bone marrow depression as a result of the treatment. The study does not provide specific details about the patient's age, sex, or the duration of treatment. [Extracted from the article]

This article presents four case reports of children aged 6-11 years who developed haematological toxicity while undergoing treatment for undifferentiated embryonal sarcoma of the liver (UESL). The patients received a combination of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide. Despite the toxicity, all patients underwent complete resection of liver tumors and received additional treatments such as radiotherapy. Remission of UESL was observed in all cases, with varying durations of remission ranging from 9 to 26 months. [Extracted from the article]

A retrospective study examined the lack of efficacy of various drugs in the treatment of choriocarcinoma in two young boys. The first case involved a 10-month-old boy who underwent multiple treatments including methotrexate, vinblastine, bleomycin, cisplatin, doxorubicin, etoposide, and ifosfamide, but unfortunately passed away due to choriocarcinoma. The second case involved a 1-month-old boy who also received treatment with etoposide, ifosfamide, and cisplatin, but also passed away due to choriocarcinoma. These cases highlight the challenges in treating choriocarcinoma in young patients. [Extracted from the article]

In a retrospective study involving 35 patients treated for leptomeningeal metastasis (LM), three patients developed hydrocephalus, sensory neurological deficits, and seizures during treatment with etoposide. The patients had been diagnosed with LM and were receiving intra-CSF etoposide, with one patient also receiving three oral chemotherapy drugs. The specific dosages, duration of treatments, and outcomes of the adverse reactions were not provided. [Extracted from the article]

In a retrospective study of 63 elderly patients with extensive-stage small-cell lung cancer (ES-SCLC), two patients developed aspiration or gastrointestinal bleeding during treatment with carboplatin and etoposide. Both patients had a history of ES-SCLC and were receiving cyclic treatment with IV carboplatin and IV etoposide. Unfortunately, both patients died as a result of these adverse drug reactions. The study highlights the potential risks associated with this treatment regimen in elderly patients. [Extracted from the article]

In a retrospective study involving 92 patients with relapsed refractory lymphoma, three patients developed fungal pneumonia, nausea, or a transient ischemic attack while receiving treatment with prednisolone, etoposide, procarbazine, and cyclophosphamide (PEP-C). The patients had been diagnosed with relapsed refractory lymphoma and were receiving a specific treatment regimen. However, they experienced adverse reactions to the medication and subsequently discontinued the treatment. The study does not provide information on the outcomes of these reactions or the duration of treatment before the reactions occurred. [Extracted from the article]

A 56-year-old man with lung squamous cell carcinoma exhibited lack of efficacy during treatment with etoposide, cisplatin, and sugemalimab. He initially showed improvement in symptoms with sugemalimab, but later experienced progressive disease. Treatment with etoposide and cisplatin also did not effectively treat the disease, and the man eventually died from lung SCC. This case highlights the lack of efficacy of these medications for this particular patient. [Extracted from the article]

A 5-month-old girl developed sinusoidal obstructive syndrome and ototoxicity during treatment for an embryonal tumor with multilayered rosettes. She presented with vomiting and somnolence, and a brain MRI revealed a tumor in the right posterior fossa. After receiving induction chemotherapy, her tumor size decreased and she underwent surgery. However, she developed sinusoidal obstructive syndrome and was treated with defibrotide. She also developed ototoxicity and required hearing aids. At the age of 6, she was attending school. [Extracted from the article]

A retrospective study of 104 patients with neuroendocrine carcinoma (NEC) found that two patients developed elevated creatinine levels while receiving treatment with cisplatin and etoposide. The patients had a history of NEC and were receiving intravenous cisplatin and etoposide. Both patients experienced grade 3 elevated creatinine levels, with levels of 3.35 mg/dL and 3.88 mg/dL. The study did not provide information on the duration of treatment or the outcomes for these patients. [Extracted from the article]

A 31-year-old woman experienced peripheral neuropathy, nausea, and constipation while undergoing treatment for immature teratoma during pregnancy. She delivered a healthy baby girl and continued treatment post-partum. The woman underwent a laparoscopy to remove an ovarian cyst and was in remission 22 months after diagnosis. The child showed no signs of developmental delay or congenital abnormalities. [Extracted from the article]

In a retrospective study, 22 patients with glioblastoma were described as developing neutropenia or pulmonary embolism during off-label treatment with trofosfamide and etoposide. The specific dosages, routes, durations of treatments, and outcomes were not provided. It was noted that the patients received off-label treatment with trofosfamide and etoposide, but experienced neutropenia (n=1) and pulmonary embolism (n=1) as a result. [Extracted from the article]

A 72-year-old man developed a tracheomediastinal fistula while undergoing treatment for limited stage small cell lung cancer (SCLC) with cisplatin and etoposide. He also experienced a lack of efficacy with pegfilgrastim, a medication used to prevent febrile neutropenia. The man presented with symptoms such as blurred vision and dysphagia, and was diagnosed with SCLC and myasthenia gravis. Despite treatment with antibiotics and reduced dosages of cisplatin and etoposide, the man developed febrile neutropenia again and was found to have a life-threatening tracheomediastinal fistula. He was treated with antibiotics and his chemotherapy was discontinued, with no further recurrence of SCLC noted. Stent placement was considered to repair the fistula. [Extracted from the article]

A 66-year-old man developed febrile neutropenia while undergoing treatment with etoposide and cisplatin for bile duct mixed neuroendocrine-nonendocrine neoplasm. He experienced back pain and epicardial pain for 3 months before being diagnosed. The man received IV etoposide and cisplatin, with the dose of etoposide increasing in the second and third courses. After two courses, he developed grade 3 febrile neutropenia, but his neoplasm improved after the third course. The article does not mention the outcome of the adverse drug reaction. [Extracted from the article]

A retrospective study examined 56 patients with small cell lung cancer who were treated with a combination of cisplatin, etoposide, and catequentinib. The study found that some patients developed thrombocytopenia and hand and foot syndrome as a result of the treatment. Thrombocytopenia was observed in one patient from the control group, while hand and foot syndrome was observed in one patient from the treatment group. The study did not provide information on the ages or sexes of the patients, the duration of treatments, or the outcomes of the reactions. [Extracted from the article]

A 29-month-old boy with osseous Ewing sarcoma exhibited lack of efficacy during treatment with doxorubicin, etoposide, and ifosfamide. The boy initially presented with swelling and pain in his arm after a fall, and a tumorous mass with a fracture was discovered. Despite receiving five cycles of chemotherapy, the sarcoma did not respond to the treatment. The boy's chemotherapy was changed, and he underwent surgery to remove the sarcoma. After further treatment and follow-up, he showed normal growth and development with no recurrence of the disease. [Extracted from the article]

A 91-year-old woman with small cell lung cancer (SCLC) experienced lack of efficacy during treatment with carboplatin and etoposide. After starting the treatment, she developed rapid onset nephrotic syndrome and was admitted to the hospital for evaluation. A kidney biopsy revealed minimal-change disease (MCD), indicating that the treatment was not effective. The woman was given corticosteroids while continuing cancer therapy, and her symptoms improved within a month. At her most recent follow-up appointment, she was still doing well. [Extracted from the article]

A 1.5-year-old boy died after receiving treatment for a CNS embryonal tumor. The boy underwent surgery and received several cycles of chemotherapy drugs, including cisplatin, vincristine, etoposide, cyclophosphamide, methotrexate, carboplatin, and thiotepa. He also experienced hypotension and veno-occlusive disease of the liver. The exact cause of death is unspecified. [Extracted from the article]

A retrospective study examined the relationship between thoracic radiotherapy (TRT) timing and adverse events in elderly patients with limited-stage small cell lung cancer (LS-SCLC). The study included 78 patients aged 60 years and older, and one patient experienced a grade 3 radiation pneumonia as a treatment-related adverse event while receiving etoposide for LS-SCLC. The specific details of the patient's age, sex, treatment regimen, and outcome were not provided in the study. [Extracted from the article]

An 11-year-old boy with familial hemophagocytic lymphohistiocytosis type 3 exhibited lack of efficacy during treatment with dexamethasone, etoposide, methotrexate, and ciclosporin. Despite the treatment, his mental status and renal function deteriorated. He received renal replacement therapy and developed acute kidney injury. After a disease relapse, he was treated with antithymocyte-globulin and experienced transient hypertension. He ultimately died of complications from myeloablative therapy. [Extracted from the article]

A woman in her early 20s developed vomiting during treatment with bleomycin, etoposide, and cisplatin for ovarian cystic teratoma. She underwent surgery and was diagnosed with grade 3 immature cystic teratoma in one ovary and mature cystic teratoma in the other. After receiving three cycles of chemotherapy, she developed excessive vomiting, leading to electrolyte imbalances. The final cycle of chemotherapy was discontinued, and her tumor markers eventually normalized. She was later diagnosed with gliomatosis peritonei. [Extracted from the article]

In a retrospective study of 99 patients with extensive disease small cell lung cancer (ED-SCLC), a patient developed interstitial pneumonia while receiving treatment with atezolizumab, carboplatin, and etoposide. The patient received intravenous atezolizumab, carboplatin, and etoposide every 3 weeks, but the dosages are not specified. The severity of the interstitial pneumonia was grade 3, but the timing of the reaction and the outcome are not mentioned. [Extracted from the article]

A retrospective study examined the relationship between thoracic radiotherapy (TRT) timing and adverse events in elderly patients with limited-stage small cell lung cancer (LS-SCLC). The study included 78 patients aged 60 years and older, and one patient experienced a grade 3 radiation pneumonia as a treatment-related adverse event while receiving etoposide for LS-SCLC. The specific details of the patient's age, sex, route of administration, dosage, duration of treatment, and outcome were not provided in the study. [Extracted from the article]

An 11-year-old boy with familial hemophagocytic lymphohistiocytosis type 3 exhibited lack of efficacy during treatment with dexamethasone, etoposide, methotrexate, and ciclosporin. Despite the treatment, his mental status and renal function deteriorated. He received renal replacement therapy and developed acute kidney injury. After treatment with methylprednisolone, his renal function improved, but he experienced a disease relapse and ultimately died of complications of myeloablative therapy. [Extracted from the article]

A woman in her early 20s developed vomiting during treatment with bleomycin, etoposide, and cisplatin for ovarian cystic teratoma. She underwent surgery and was diagnosed with grade 3 immature cystic teratoma in one ovary and mature cystic teratoma in the other. After receiving three cycles of chemotherapy, she developed excessive vomiting, leading to electrolyte imbalances. The final cycle of chemotherapy was discontinued, and her tumor markers eventually normalized. She was later diagnosed with gliomatosis peritonei. [Extracted from the article]

In a retrospective study of 99 patients with extensive disease small cell lung cancer (ED-SCLC), a patient developed interstitial pneumonia while receiving treatment with atezolizumab, carboplatin, and etoposide. The patient received intravenous atezolizumab, carboplatin, and etoposide every 3 weeks, but the dosages are not specified. The severity of the interstitial pneumonia was grade 3, but the timing of the reaction and the outcome are not mentioned. [Extracted from the article]

A case series was conducted on four patients with adult-onset still's disease (AOSD), macrophage activation syndrome (MAS), and other related conditions. The patients were treated with medications such as methylprednisolone, etoposide, and prednisone, but did not experience a therapeutic response or showed lack of efficacy. Despite the lack of response to initial treatments, the patients were eventually treated with anakinra and dexamethasone, which led to improvements in their conditions. These findings suggest that alternative treatments may be necessary for patients with AOSD and MAS who do not respond to conventional therapies. [Extracted from the article]

A 9-year-old boy with a history of haemophagocytic lymphohistiocytosis (HLH) experienced a lack of efficacy during treatment with etoposide. He presented with blurred vision in his right eye and was diagnosed with infiltrative optic neuropathy secondary to HLH. Despite receiving etoposide chemotherapy and radiotherapy, his disease continued to progress, leading to a deterioration of his vision. This case suggests that etoposide may not be effective in treating HLH in this particular patient. [Extracted from the article]

A female neonate with haemophagocytic lymphohistiocytosis (HLH) was treated with etoposide and dexamethasone but did not respond to the treatment. The neonate initially presented with acute liver failure and acute kidney injury, and was diagnosed with disseminated neonatal herpes simplex virus (HSV)-1 infection. Despite receiving continuous renal replacement therapy (CRRT) and other treatments, her condition worsened and she eventually died due to HLH, shock, and metabolic acidosis. This case highlights the lack of efficacy of etoposide and dexamethasone in this particular patient. [Extracted from the article]

A 61-year-old man experienced sepsis while undergoing treatment for choriocarcinoma with the drugs etoposide, ifosfamide, and cisplatin. The patient had pre-existing conditions including hypertension, chronic hepatitis C, and chronic obstructive pulmonary disease. He initially presented with symptoms of cauda equina syndrome and was subsequently diagnosed with choriocarcinoma. Despite completing the first cycle of chemotherapy and receiving antibiotics, his condition worsened and he eventually transitioned to comfort care. [Extracted from the article]

A 33-year-old man developed acute heart failure while undergoing treatment for a mixed germ cell tumor. The treatment involved the drugs etoposide, ifosfamide, and cisplatin. The man experienced dyspnea and lower limb edema, and tests revealed a reduced left ventricle ejection fraction. He was diagnosed with acute heart failure caused by the treatment. After receiving treatment with β-blockers, angiotensin-converting enzyme inhibitors, and diuretics, the man showed clinical improvement and his left ventricle ejection fraction increased. [Extracted from the article]

A 61-year-old man with a history of large cell neuroendocrine neoplasm of the lung with small cell components/features experienced lack of efficacy during treatment with cisplatin/etoposide. He presented with refractory hypokalemia and depressive symptoms, and further evaluation revealed elevated serum cortisol and adrenocorticotropic hormone (ACTH). The patient was diagnosed with Cushing's syndrome due to ectopic ACTH-production from the lung tumor. Despite treatment attempts, the patient experienced disease progression and ultimately passed away. [Extracted from the article]

A 72-year-old woman with metastatic adrenocortical carcinoma (ACC) developed cardiotoxicity after receiving treatment with cisplatin, etoposide, and doxorubicin. She had a history of Cushing's syndrome and underwent robotic resection of an adrenal adenoma. Following the resection, metastatic ACC was discovered, and she started receiving the aforementioned chemotherapy drugs. However, she experienced cardiotoxicity and the chemotherapy regimen was discontinued, with only mitotane continued as therapy. [Extracted from the article]

A retrospective study of 33 patients with high-risk neuroblastoma (HR-NBL) found that four patients developed different types of cancers during treatment with carboplatin, etoposide, and melphalan. The patients received various chemotherapy regimens before undergoing peripheral stem cell transplantation. After the transplant, they received high-dose chemotherapy with melphalan, etoposide, and carboplatin. The patients subsequently developed myelodysplastic syndrome, renal cell carcinoma, squamous cell carcinoma, and rhabdomyosarcoma as a result of the treatment. The timing and outcomes of these adverse reactions were not provided. [Extracted from the article]

A 20-year-old man with adrenocortical carcinoma and lung and liver metastases exhibited lack of efficacy during treatment with mitotane, carboplatin, and etoposide. The patient had a history of cigarette smoking and marijuana use and presented with new onset heart failure. He received various treatments including etomidate, dexamethasone, furosemide, doxazosin, ketoconazole, and cotrimoxazole. Despite these interventions, there was a continued increase in adrenal mass size, leading to the conclusion that the initial treatment regimen was ineffective. The patient subsequently received treatment with pembrolizumab. [Extracted from the article]

A 9-year-old girl with recurrent metastatic neuroblastoma developed oral mucositis and febrile pancytopenia while receiving carboplatin and etoposide as second-line chemotherapy. She experienced severe pain in the oral cavity and oropharynx, along with drooling, speech difficulty, dysphagia, and weight loss. Treatment included tocopherol for lip hydration, chlorhexidine for oral hygiene, debris removal, photobiomodulation, and various medications. The oral mucositis eventually resolved, but the girl ultimately died, with the cause of death not specified. [Extracted from the article]

A 14-year-old girl experienced bone marrow suppression and immunosuppression while being treated with etoposide and carboplatin for intracranial multifocal germinoma. She underwent surgery to remove the tumor and started cyclical treatment with the medications. However, she developed bone marrow suppression, severe intracranial infection, and transient liver injury. She received symptomatic treatment and radiation therapy, but still experienced grade IV bone marrow suppression. She was readmitted to the hospital and received various treatments to address her condition, including dexamethasone for secondary hemophagocytic lymphohistiocytosis. After several months of treatment, her condition improved, and she was considered to be in good health. [Extracted from the article]

A 15-year-old boy with primary mediastinal yolk sac tumor underwent treatment with the BEP regimen (bleomycin, etoposide, and cisplatin). However, the treatment did not reduce the size of the tumor and his serum AFP levels remained high, indicating a lack of efficacy. The boy underwent surgery to remove the tumor and other affected tissues, and he recovered well without complications. Follow-up examinations showed normal levels of serum AFP and no recurrence of the tumor. [Extracted from the article]

A 51-year-old man with metastatic small cell carcinoma of unknown origin experienced a lack of efficacy during treatment with carboplatin, etoposide, and atezolizumab. The patient had a history of type 2 diabetes mellitus and hypertension and presented with angioedema. Despite receiving five cycles of the initial treatment, progression of mediastinal adenopathy was observed. The patient underwent a tracheostomy and imaging revealed metastatic pheochromocytoma and paraganglioma. His chemotherapy was changed to vincristine, dacarbazine, and cyclophosphamide, resulting in improvement. [Extracted from the article]

A 73-year-old man with stage IIB small cell lung cancer exhibited lack of efficacy during treatment with cisplatin and etoposide. Despite undergoing surgery, adjuvant chemotherapy, and radiation therapy, he developed tracheal metastasis of small cell lung cancer. He then received radiation therapy again and continued with a different chemotherapy regimen. The patient remained recurrence-free after 61 months of surgery. [Extracted from the article]